Sector Alpha Week of 2026-08-05
Sector Alpha — machine-written from the numbers · Data as of 2026-08-05

Veeva Systems Inc.

VEEV
Healthcare · Health Information Services

Veeva Systems Inc.'s earnings have outrun its stock. EPS grew +25.9% in a year against a −24.7% price move.

The sharpest disagreement: annual EPS moved +25.9% against a −24.7% price move — the market has not yet caught up with the delivery.

The price is topping out (1 weeks in) while the P/E sits at the 12th percentile of its own 4-year range. Underneath, the last four quarters read improving — profit +13.0% year on year, and 159% of the last 3 years' profit arrived as cash. What settles it: whether the price catches up with earnings that have already moved.

Stage
Mixed
fundamental trajectory, 12 quarters
Price
$212
−24.7% 1Y
P/E
37.6×
12th pctile
of its own 4-year range
Revenue (Apr 26)
$0.9 B
+15.8% YoY
Profit (Apr 26)
$0.3 B
+13.0% YoY
Operating margin
30.7%
+0.4 pp YoY
ROE
14%
FY26
ROIC
176.9%
vs WACC 9.4% → +167.5 pp
Cash conversion
159%
of profit, last 3 FY
01 · Price story

Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.

Veeva Systems Inc. trades at $212, losing momentum at the top and 1 weeks into that stage. That is +4.3% against its own 200-day average. It sits at 42% of a 52-week range of $151 to $296. On relative strength it has been ahead of the S&P 500 on a trailing-13-week view for 5 straight weeks.

Today the stock is losing momentum at the top — week 1 of stage 3. At $212 it trades +4.3% versus its 200-day average and sits at 42% of its 52-week range ($151–$296).

Aug 26: $212 Weekly closing price ($) with 50- and 200-day averages; shaded bands mark the price stage (grey base, green advance, amber top, red decline). 3-year window.
+4.3% versus the 200-day line, week 1 of stage 3
Price50-day avg200-day avg
S2S1S2S2S1S4$308$266$224$182$140$$212$203Jul 23Apr 24Jan 25Oct 25Aug 26
S2S1S2S2S1S4$308$266$224$182$140$$212$203Jul 23Jan 25Aug 26
Beating or trailing, week by week since 2016 Each cell is one week from 2016 to now (527 weeks): the stock's trailing 13-week return minus the S&P 500's, green ahead / red behind (±25% ramp). Grey cells are the 13-week warm-up or weeks where the S&P 500 reading is not held.
trailing 13-week return vs the S&P 500
Jul 16Aug 26

Against the market, two honest reads. Cumulative: over the last 10.1 years the stock moved +467% while the S&P 500 moved +263% — ahead of the index over the full window. Recent form: on a trailing-13-week view the stock has been ahead for 5 straight weeks — the ribbon below is that same metric, week by week.

What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.

02 · Valuation

Valuation P/E is the price of $1 of annual profit: how many dollars the market pays for each dollar the company earns in a year.

Veeva Systems Inc. trades at 37.6× P/E, near the bottom of its own range — cheaper only 12% of the time. Its long-run median P/E is 57.4×, measured across 4.2 years of weekly readings. This places the multiple against the stock’s own record, and says nothing about what the business is worth.

Today's P/E of 37.6× is near the bottom of its own range — cheaper only 12% of the time, against a long-run median of 57.4× measured over 4.2 years of weekly readings. This is a comparison against the stock's own history — not a claim about what it is worth.

One caveat before moving on: margins are the best this company has ever printed — cheap against its own history on record margins is not the same thing as cheap. If profitability mean-reverts, today's multiple is higher than it looks.

P/E 37.6× vs a 57.4× long-run median P/E, weekly (left axis); earnings per share, trailing twelve months, weekly step line (right axis). 4.2-year window; loss-period spikes above 85× shown pinned at the top. The eps (ttm) bars are red where the reading is lower than the quarter before.
near the bottom of its own range — cheaper only 12% of the time
P/EMedianEPS (TTM) (quarterly)
89.6×$6.172.9×$4.556.2×$3.039.4×$1.522.7×$0.0×$37.76×$6May 22May 23Jun 24Jul 25Aug 26
89.6×$6.172.9×$4.556.2×$3.039.4×$1.522.7×$0.0×$37.76×$6May 22Jun 24Aug 26
PEG 0.82 PEG ratio per quarter — the P/E divided by the earnings-growth rate. The dashed line marks 1.0: below it the growth is cheap against the multiple, above it the price already prices the growth in. Last 19 quarters.
below 1.0, the growth looks cheap against the multiple
PEGPEG = 1.0
5.0×3.9×2.7×1.6×0.5××0.82×Oct 21Oct 22Jan 24Jan 25Apr 26
5.0×3.9×2.7×1.6×0.5××0.82×Oct 21Jan 24Apr 26
P/E
37.6×
12th percentile of 4y
PEG
1.07
as reported

Why the multiple sits where it does: over the past year annual EPS moved +25.9% against a −24.7% price move — earnings outran the price, pushing the multiple DOWN its own range.

The price move, decomposed: over 3y, of the +2.5%/yr price move, ~+19.1%/yr came from earnings growth and ~−16.6 pp from the multiple (compressing). The split is the honest approximate (price return minus earnings growth); it makes the rally itself visible instead of hiding it behind the percentile.

Put together: the multiple is low against its own past, so the story rests on the earnings line underneath it, not the multiple.

03 · Stage: Mixed

Stage: Mixed Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).

Veeva Systems Inc. reads as mixed on its fundamental arc. Mixed — no clean majority across the growth curves, ROCE holding at 9.9% — the per-curve reads carry the story. The read is built from 12 quarters across 4 curves, on full evidence.

Growth, year by year: revenue +16.4% in FY26, profit +28.2% Year-over-year growth per fiscal year, %: revenue (left axis); net profit and EPS (right axis — profit growth swings far wider). Zero line drawn.
Revenue YoYProfit YoYEPS YoY
17%36%15%29%13%21%11%13%8.7%5.1%%%16.4%28.2%FY22FY24FY26
17%36%15%29%13%21%11%13%8.7%5.1%%%16.4%28.2%FY22FY24FY26
Three growth curves, twelve quarters Year-on-year growth of trailing-twelve-month revenue (left axis), profit and EPS (right axis — they swing far wider), % at each quarter-end. A missing point means that reading is not held for the quarter.
the trajectory the stage is read from · revenue stabilising, profit rolling over
RevenueProfitEPS
17%45%15%35%13%24%12%14%9.7%3.0%%%16.1%19%18.9%Jul 23Oct 24Apr 26
17%45%15%35%13%24%12%14%9.7%3.0%%%16.1%19%18.9%Jul 23Oct 24Apr 26
ROCE Trailing-twelve-month operating profit (before interest and tax) as a share of average capital employed — total assets minus current liabilities, the standard textbook basis, %.
the return curve, computed quarterly
ROCE
16%14%12%10%8.5%%9.9%Jul 23Jan 24Oct 24Jul 25Apr 26
16%14%12%10%8.5%%9.9%Jul 23Oct 24Apr 26
Revenue growth
Steady high
latest +16.1% · span +10.2% to +16.4%
Profit growth
Rolling over
latest +19.0% · span +7.7% to +42.5%
EPS growth
Rolling over
latest +18.9% · span +5.9% to +42.0%
ROCE
Stuck low
latest 9.9% · span 9.0%–15.3%

Why it matters: when the curves disagree, the per-curve reads above matter more than any single verdict.

Compound annual growth rate (%) Compound annual growth rate over each window, %. Revenue, profit and EPS from fiscal-year figures; stock price is the price CAGR over the same spans. A dash = that window is not held, or the base was a loss.
1yr3yr5yr10yr
Revenue+16.4%+14.0%
Profit+28.2%+22.9%
EPS+25.9%+21.9%
Stock price−24.7%+2.5%−9.0%+18.7%
Revenue YoY (Apr 26)
+15.8%
latest quarter vs a year ago
Profit YoY (Apr 26)
+13.0%
latest quarter vs a year ago
Revenue 10y
14.7%
long-run compound pace
04 · 4-Factor Sector Score

4-Factor Sector Score

61.5/100 — rank 4 of 29 in Health Information Services · 85% evidence confidence

Veeva Systems Inc. scores 61.5 out of 100 against the 29 companies it is compared with in Health Information Services, ranking 4. Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.

The four contributions add to the total exactly: 20.5 + 17.7 + 13.8 + 9.5 = 61.5. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.

What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.

05 · Revenue

Revenue Revenue is the top line: everything the company billed its customers in the period.

Veeva Systems Inc. reported $0.9 B of revenue in the Apr 26 quarter, +15.8% year on year. That is the 12th straight quarter of year-on-year growth. Over 4 years it has compounded at 14.7% a year. The last full year, FY26, came in at $3.2 B. The last four reported quarters add to $3.3 B.

FY26 revenue came in at $3.2 B (+16.4% on the year), capping 4 years at 14.7% compound. The latest quarter (Apr 26) printed $0.9 B, +15.8% year on year — the 12th consecutive quarter of year-over-year growth.

FY26 revenue $3.2 B (+16.4% YoY) Revenue bars, $ B (left); YoY growth-% line (right). 5-year window. A bar is red when it is lower than the year before.
14.7% a year over 4 years
RevenueYoY growth
3.517%2.615%1.713%0.911%0.08.7%$ B%$3B16.4%FY22FY24FY26
3.517%2.615%1.713%0.911%0.08.7%$ B%$3B16.4%FY22FY24FY26
Apr 26: $0.9 B (+15.8% YoY) Quarterly revenue bars, $ B (left); YoY growth-% line (right). Last 12 quarters. A bar is red when it is lower than the quarter before.
12th straight quarter of growth
Revenue (quarterly)YoY growth
1.024%0.720%0.517%0.214%0.010%$ B%$1B15.8%Jul 23Oct 24Apr 26
1.024%0.720%0.517%0.214%0.010%$ B%$1B15.8%Jul 23Oct 24Apr 26

Pace check: the last four quarters averaged +16.1% growth against the decade's 14.7% — the current year is running faster than its own long-run rate.

Acceleration check: trailing-twelve-month revenue grew +16.1% over the last 4 quarters against +15.5%/yr over the last 8 — stabilising; TTM profit +19.0% vs +29.6%/yr — rolling over.

06 · Operating margin

Operating margin Operating margin is what is left of every $100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.

Veeva Systems Inc.'s operating margin is 30.7% in the Apr 26 quarter, +0.4 percentage points against the same quarter a year ago. That is the widest this company has ever printed on a full-year basis. Across 5 fiscal years the operating margin has ranged 18.2% to 28.7%. The current quarter is running above every full year in that window.

The latest quarter's operating margin is 30.7%, +0.4 pp against the same quarter a year ago. Across 5 fiscal years the operating margin has ranged 18.2%–28.7%, and FY26's 28.7% is the top of that band — a record year.

Why the margin moved: operating margin went +0.4 pp year on year while gross margin went −2.6 pp — the gain came mostly from the gross line: input costs and pricing.

Worth repeating from the valuation section: cheap against its own history on record margins is not the same thing as cheap — a record margin flatters every ratio built on top of it.

FY26: 28.7% Operating margin by fiscal year, %, line (left); year-on-year change in the margin, in percentage points, line (right). 5-year window.
the widest a 18.2–28.7% band over 5 years
operating marginYoY change (pp)
30%8.0%26%4.1%23%0.3%20%−3.5%17%−7.4%%%28.7%3.6%FY22FY24FY26
30%8.0%26%4.1%23%0.3%20%−3.5%17%−7.4%%%28.7%3.6%FY22FY24FY26
Apr 26: 30.7% operating margin (+0.4 pp YoY) Quarterly operating margin, %, line (left); year-on-year change in the margin, in percentage points, line (right). Last 12 quarters. Operating profit as a share of revenue, per quarter.
Operating marginYoY change (pp)
50%27%31%8.3%12%−11%−7.1%−29%−26%−48%%%30.7%0.4%Jul 23Oct 24Apr 26
50%27%31%8.3%12%−11%−7.1%−29%−26%−48%%%30.7%0.4%Jul 23Oct 24Apr 26
07 · Net profit

Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.

Veeva Systems Inc. earned $0.3 B of net profit in the Apr 26 quarter, +13.0% year on year. It is the 9th consecutive quarter of growth. Full-year FY26 profit was $0.9 B. The 4-year compound rate is 20.6%. That is 29.5% of the quarter's revenue. The same quarter a year earlier earned $0.2 B.

Apr 26 profit was $0.3 B, +13.0% year on year — the 9th consecutive quarter of growth. On the full year, FY26 printed $0.9 B (+28.2%), and the 4-year compound rate is 20.6%.

FY26 profit $0.9 B (+28.2% YoY) Net profit bars, $ B (left); YoY growth-% line (right). 5-year window. A bar is red when it is lower than the year before.
20.6% a year over 4 years
Net profitYoY growth
1.036%0.729%0.521%0.214%0.06.1%$ B%$1B28.2%FY22FY24FY26
1.036%0.729%0.521%0.214%0.06.1%$ B%$1B28.2%FY22FY24FY26
Apr 26: $0.3 B (+13.0% YoY) Quarterly net profit bars, $ B (left); YoY growth-% line (right). Last 12 quarters. A bar is red when it is lower than the quarter before.
9th straight quarter of growth
Net profit (quarterly)YoY growth
0.2861%0.2139%0.1417%0.07−5.2%0.00−27%$ B%$0B13%Jul 23Oct 24Apr 26
0.2861%0.2139%0.1417%0.07−5.2%0.00−27%$ B%$0B13%Jul 23Oct 24Apr 26

Why profit moved: revenue contributed +15.8% and the margin +0.4 pp — the quarter was revenue-led, with the margin roughly flat.

Pace comparison, last four quarters: profit +19.2% vs revenue +16.1%. Profit is growing faster than sales — fixed costs are being spread over a bigger base, and each extra dollar of revenue drops more to the bottom line.

08 · Cash flow — the router

Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.

Over the last 3 fiscal years 159% of Veeva Systems Inc.'s reported profit arrived as operating cash — the cash follows the profit. In FY26 that was $1.4 B of operating cash against $0.9 B of profit. After null of capital spending, $1.4 B was left as free cash.

FY26: operating cash of $1.4 B against reported profit of $0.9 B, leaving free cash of $1.4 B after null of capital spending. Across the last 3 fiscal years the conversion rate is 159% of profit.

Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.

FY26: CFO $1.4 B vs profit $0.9 B Operating cash flow and net profit by fiscal year, $ B; the line is free cash flow (CFO minus capital spending). 5-year window, annual resolution.
159% of 3-year profit arrived as cash
Operating cashNet profitFree cash
1.51.20.80.40.0$ B$1B$1B$1BFY22FY24FY26
1.51.20.80.40.0$ B$1B$1B$1BFY22FY24FY26
Apr 26: operating cash $1.1 B = 435% of the quarter's profit Operating cash per quarter, $ B (bars); conversion = operating cash as % of net profit (line, right). Last 12 quarters. Dashed line = 100%.
Operating cash (quarterly)Conversion100%
1.2510%0.9383%0.6255%0.3127%0.00.0%$ B%$1B435%Jul 23Oct 24Apr 26
1.2510%0.9383%0.6255%0.3127%0.00.0%$ B%$1B435%Jul 23Oct 24Apr 26

Why: conversion is measured cleanly, but the working-capital day-counts behind it sit below what we hold — the move is shown without inventing its driver.

Router verdict: no single sink dominates — the next section checks both the working-capital cycle and the capital spending.

09 · Where the cash goes

Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).

Veeva Systems Inc. does not report the debtor, inventory and payable day-counts a cash cycle is built from, so this section reads the investment side instead. Nothing is estimated in place of the missing day-counts, so no cash-cycle chart is drawn.

Working-capital day-counts are not in our numbers for this stock, so this section reads the investment side — where the cash is being put to work.

The synthesis: neither the cycle nor the build-out is hoarding the cash — the machine is reasonably clean.

10 · Return on equity

Return on equity Return on equity (ROE) is the profit the business earns on its shareholders’ money. With the full capital-employed split not in our numbers, ROE is the cleanest long ladder we can draw here.

Veeva Systems Inc. earns a ROE of 13% in FY26. That is up from a trough of 11% in FY24. Return on invested capital clears the cost of that capital by +167.5 percentage points, so growth here adds value rather than only size. The wiring behind it is 28.4% net margin on 0.36× asset turns.

FY26 ROE is 13%, recovered from a FY24 trough of 11% — the full ladder below shows the fall and the climb, undoctored.

Why the return is what it is — the wiring (FY26): 28.4% net margin × 0.36× asset turns × 1.25× balance-sheet leverage ≈ 12.8% on equity. Margin is doing the heavy lifting; leverage is modest — this is an earned return, not a borrowed one.

The capstone test — ROIC − WACC: 176.9% − 9.4% = a +167.5 pp spread. The 9.4% is an estimate of this company's own cost of capital — read the sign and the size of the spread, not the decimals. A spread this wide means every dollar reinvested creates more than a dollar of value — the engine compounds.

FY26: ROE 13% Return on equity by fiscal year, % (line); ROIC by fiscal year, % (line). 5-year window, dips included. Dashed line = the 9.4% cost of capital used on this page.
the climb back from FY24's 11%
ROEROIC (annual)WACC
99%75%51%27%2.8%%12.6%92.5%FY22FY24FY26
99%75%51%27%2.8%%12.6%92.5%FY22FY24FY26
Apr 26: ROIC 130.6% (TTM) vs WACC 9.4% Trailing-twelve-month ROIC and ROE, per quarter, %; dashed line = the cost of capital. Last 12 quarters, put on a trailing-twelve-month basis and anchored to the annual figure.
ROIC (TTM)ROE (TTM)WACC
166%124%82%40%−2.2%%130.6%14.8%Jul 23Oct 24Apr 26
166%124%82%40%−2.2%%130.6%14.8%Jul 23Oct 24Apr 26
11 · Dividend

Dividend

Veeva Systems Inc. pays no dividend. Across the last 12 reported quarters it has declared no dividend per share, so there is no payout history to chart and no yield to quote. Companies at this stage typically reinvest earnings rather than distribute them, which makes the cash-flow and reinvestment sections the place that cash shows up.

Veeva Systems Inc. does not currently pay a dividend. Across the last 12 reported quarters the company has declared no dividend per share, so there is no payout history to chart and no yield to quote. Companies at this stage typically reinvest earnings instead of distributing them.

12 · Debt

Debt Debt-to-equity says how much of the business is funded by borrowings. Low is the safe corner; the trend matters as much as the level.

Veeva Systems Inc. carries total debt of $0.1 B against shareholder equity of $7.3 B as of Apr 26, a debt-to-equity of 0.01 — effectively unlevered. On the annual view that ratio went from 0.02 in FY22 to 0.01 in FY26. The returns elsewhere on this page are therefore earned rather than borrowed.

Apr 26: total debt of $0.1 B against shareholder equity of $7.3 B — a debt-to-equity of 0.01. On the annual view, debt-to-equity went from 0.02 (FY22) to 0.01 (FY26). The returns on this page are earned, not borrowed.

FY26: debt $0.1 B at 0.01× equity Total debt by fiscal year, $ B (bars); debt-to-equity, × (line). 5-year window.
Total debtDebt-to-equity
0.110.021×0.080.018×0.050.015×0.030.012×0.000.009×$ B×$0B0.01×FY22FY24FY26
0.110.021×0.080.018×0.050.015×0.030.012×0.000.009×$ B×$0B0.01×FY22FY24FY26
Apr 26: debt $0.1 B, debt-to-equity 0.01 Total debt per quarter, $ B (bars); debt-to-equity, × (line). Last 12 quarters.
Total debt (quarterly)Debt-to-equity
0.111.2×0.080.6×0.050.0×0.03−0.6×0.00−1.1×$ B×$0B0.01×Jul 23Oct 24Apr 26
0.111.2×0.080.6×0.050.0×0.03−0.6×0.00−1.1×$ B×$0B0.01×Jul 23Oct 24Apr 26
13 · Ownership

Ownership There is no quarter-by-quarter holder register to read here, so we read the crowd through short interest — the slice of tradable shares currently sold short, positioned for a fall.

5.3% of Veeva Systems Inc.'s tradable float is currently sold short — some money is positioned against it. At typical trading volumes those positions would take about 3.2 days to buy back. There is no quarter-by-quarter holder register to read for this filer, so the crowd is read through short interest instead.

The latest reading: 5.3% of the float is sold short, and at typical trading volumes it would take about 3.2 days to buy those positions back. Some money is positioned against it. This is a single point-in-time reading — we do not yet hold its history, so we show no trend chart.

Short interest
5.3%
of the tradable float
Days to cover
3.2
at typical volumes

Why it sits there: who is doing the shorting, and why, does not travel with the number — the level is shown without inventing its story.

14 · Safety line

Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.

Veeva Systems Inc.: the Z-score reads 15.38. A Z-score above roughly 3 reads as safe and below roughly 1.8 as the distress zone, so this sits well clear of distress. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure.

Why it matters: a Z-score of 15.38 sits well clear of the distress zone — the balance sheet is not the risk here.

The safety line in one sentence: the Z-score reads 15.38.

15 · Related companies · Health Information Services
CompanyScorePrice stageGrowth & earnings/35Capital efficiency/25Valuation/20Relative strength/20
1HealthEquity, Inc.HQY 67.9/100Favorable setup85% evidence BREAKING OUT 23.6/35 Revenue 7.6% · PAT 89.3% · OPM change 3.9 pp 95% evidence 15.5/25 ROCE 3.2% · OPM 29% 76% evidence 12.4/20 P/E 30.7× · PEG 1.57 65% evidence 16.4/20 RS sector 4.3% · RS bench 5.3% · 1Y 12.8%5 of 12 weeks ahead 100% evidence
Exact sum: 23.6 + 15.5 + 12.4 + 16.4 = 67.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
2Simulations Plus, Inc.SLP 64.2/100Thin evidence · provisional52% evidence LEADER 24.6/35 Revenue — · PAT — · OPM change 11.1 pp 45% evidence 16.2/25 ROCE 3.4% · OPM 23.2% 76% evidence 10.3/20 P/E 42.8× · PEG — 15% evidence 13.1/20 RS sector 2.4% · RS bench 3.2% · 1Y 29.5%12 of 12 weeks ahead 70% evidence
Exact sum: 24.6 + 16.2 + 10.3 + 13.1 = 64.2 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
3Hinge Health, Inc.HNGE 61.7/100Mixed-positive evidence62% evidence LEADER 19.9/35 Revenue 49.5% · PAT -1748.4% · OPM change 7 pp 83% evidence 15.1/25 ROCE 8.4% · OPM 17.6% 76% evidence 10.0/20 P/E — · PEG — 0% evidence 16.7/20 RS sector 35% · RS bench 35.8% · 1Y 40.1%12 of 12 weeks ahead 70% evidence
Exact sum: 19.9 + 15.1 + 10 + 16.7 = 61.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
4Veeva Systems Inc.this pageVEEV 61.5/100Mixed-positive evidence85% evidence BREAKING OUT 20.5/35 Revenue 16.3% · PAT 20.5% · OPM change 0.1 pp 95% evidence 17.7/25 ROCE 4% · OPM 30.9% 76% evidence 13.8/20 P/E 27.8× · PEG 1.47 65% evidence 9.5/20 RS sector -12.6% · RS bench -13% · 1Y -24.9%5 of 12 weeks ahead 100% evidence
Exact sum: 20.5 + 17.7 + 13.8 + 9.5 = 61.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
510x Genomics, Inc.TXG 56.9/100Mixed-positive evidence61% evidence LEADER 20.1/35 Revenue 2.2% · PAT — · OPM change 14.1 pp 62% evidence 6.8/25 ROCE -2% · OPM -11.3% 76% evidence 10.0/20 P/E — · PEG — 0% evidence 20.0/20 RS sector 91.7% · RS bench 96.6% · 1Y 289.4%12 of 12 weeks ahead 100% evidence
Exact sum: 20.1 + 6.8 + 10 + 20 = 56.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
6BrightSpring Health Services, Inc.BTSG 56.2/100Thin evidence · provisional58% evidence LEADER 19.7/35 Revenue — · PAT — · OPM change 1.6 pp 45% evidence 12.7/25 ROCE 2.9% · OPM 3.4% 76% evidence 10.1/20 P/E 44.4× · PEG — 15% evidence 13.7/20 RS sector 27.5% · RS bench 31.3% · 1Y 202.1%12 of 12 weeks ahead 100% evidence
Exact sum: 19.7 + 12.7 + 10.1 + 13.7 = 56.2 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
7HealthStream, Inc.HSTM 55.8/100Mixed-positive evidence81% evidence BREAKING OUT 19.0/35 Revenue 6.5% · PAT 5.3% · OPM change 3.3 pp 83% evidence 14.2/25 ROCE 1.9% · OPM 9.3% 76% evidence 5.6/20 P/E 30.9× · PEG 4.87 65% evidence 17.0/20 RS sector 8.6% · RS bench 9.2% · 1Y 14.7%11 of 12 weeks ahead 100% evidence
Exact sum: 19 + 14.2 + 5.6 + 17 = 55.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
8Omada Health, Inc.OMDA 53.6/100Thin evidence · provisional55% evidence BREAKING OUT 25.2/35 Revenue 49% · PAT — · OPM change 9.2 pp 62% evidence 7.0/25 ROCE -2.9% · OPM -6.1% 76% evidence 10.0/20 P/E — · PEG — 0% evidence 11.4/20 RS sector 1.2% · RS bench 0.6% · 1Y 6.1%12 of 12 weeks ahead 70% evidence
Exact sum: 25.2 + 7 + 10 + 11.4 = 53.6 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
9Phreesia, Inc.PHR 49.2/100Mixed-negative evidence67% evidence BREAKING OUT 22.7/35 Revenue 13.8% · PAT 100% · OPM change 8 pp 71% evidence 10.9/25 ROCE 1.7% · OPM 5.2% 76% evidence 9.7/20 P/E 61.4× · PEG — 15% evidence 5.9/20 RS sector -34.4% · RS bench -35.7% · 1Y -57.6%5 of 12 weeks ahead 100% evidence
Exact sum: 22.7 + 10.9 + 9.7 + 5.9 = 49.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
10Omnicell, Inc.OMCL 47.3/100Thin evidence · provisional58% evidence ASLEEP 21.4/35 Revenue — · PAT — · OPM change 9.7 pp 45% evidence 12.8/25 ROCE 2.1% · OPM 5.4% 76% evidence 9.9/20 P/E 49.4× · PEG — 15% evidence 3.2/20 RS sector -15.2% · RS bench -13.5% · 1Y 20.5%5 of 12 weeks ahead 100% evidence
Exact sum: 21.4 + 12.8 + 9.9 + 3.2 = 47.3 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
11SOPHiA GENETICS SASOPH 47.0/100Thin evidence · provisional55% evidence BREAKING OUT 17.4/35 Revenue 19.1% · PAT — · OPM change 10.5 pp 62% evidence 3.6/25 ROCE -15.1% · OPM -79.7% 76% evidence 10.0/20 P/E — · PEG — 0% evidence 16.0/20 RS sector 26.6% · RS bench 29.3% · 1Y 115.1%6 of 12 weeks ahead 70% evidence
Exact sum: 17.4 + 3.6 + 10 + 16 = 47 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
12Weave Communications, Inc.WEAV 46.5/100Thin evidence · provisional55% evidence BREAKING OUT 21.7/35 Revenue 16.4% · PAT — · OPM change 7.5 pp 62% evidence 5.6/25 ROCE -5.1% · OPM -9.2% 76% evidence 10.0/20 P/E — · PEG — 0% evidence 9.2/20 RS sector -2.5% · RS bench -2.2% · 1Y -9.2%8 of 12 weeks ahead 70% evidence
Exact sum: 21.7 + 5.6 + 10 + 9.2 = 46.5 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
13Waystar Holding Corp.WAY 46.1/100Thin evidence · provisional58% evidence TURNING 16.6/35 Revenue — · PAT — · OPM change 0.2 pp 45% evidence 12.6/25 ROCE 1.5% · OPM 25.6% 76% evidence 11.0/20 P/E 29.3× · PEG — 15% evidence 5.9/20 RS sector -25.5% · RS bench -25.7% · 1Y -31.3%1 of 12 weeks ahead 100% evidence
Exact sum: 16.6 + 12.6 + 11 + 5.9 = 46.1 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
14NRC HealthNRC 45.7/100Thin evidence · provisional52% evidence FADING 12.6/35 Revenue — · PAT — · OPM change -9.6 pp 45% evidence 11.5/25 ROCE -3.1% · OPM 16% 76% evidence 9.0/20 P/E 86.3× · PEG — 15% evidence 12.6/20 RS sector 1.5% · RS bench 3.4% · 1Y 29.7%9 of 12 weeks ahead 70% evidence
Exact sum: 12.6 + 11.5 + 9 + 12.6 = 45.7 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
15TruBridge, Inc.TBRG 45.3/100Thin evidence · provisional58% evidence 10.9/35 Revenue 0% · PAT — · OPM change -5.9 pp 62% evidence 10.0/25 ROCE 0.9% · OPM 3.5% 76% evidence 9.2/20 P/E 73.2× · PEG — 15% evidence 15.2/20 RS sector 5.2% · RS bench 11% · 1Y 18.9%8 of 8 weeks ahead to 2026-07-10 70% evidence
Exact sum: 10.9 + 10 + 9.2 + 15.2 = 45.3 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
16Carlsmed, Inc.CARL 45.2/100Thin evidence · provisional55% evidence BREAKING OUT 21.3/35 Revenue 75% · PAT — · OPM change -1.5 pp 62% evidence 4.2/25 ROCE -11.7% · OPM -57.6% 76% evidence 10.0/20 P/E — · PEG — 0% evidence 9.7/20 RS sector -2.3% · RS bench -1.5% · 1Y 5.6%4 of 12 weeks ahead 70% evidence
Exact sum: 21.3 + 4.2 + 10 + 9.7 = 45.2 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
17Privia Health Group, Inc.PRVA 44.2/100Mixed-negative evidence81% evidence ASLEEP 22.8/35 Revenue 24.7% · PAT 40% · OPM change 0.1 pp 83% evidence 11.1/25 ROCE 1% · OPM 1.2% 76% evidence 4.7/20 P/E 128.6× · PEG 3.86 65% evidence 5.6/20 RS sector -10.3% · RS bench -9.2% · 1Y 15.6%4 of 12 weeks ahead 100% evidence
Exact sum: 22.8 + 11.1 + 4.7 + 5.6 = 44.2 · Decision use: Acceleration candidate, not a confirmed leader: earnings are strong but sector-relative strength is -10.3% and the one-year return is 15.6%. Do not upgrade until sector-relative strength is above zero and another reported period confirms growth.
18GoodRx Holdings, Inc.GDRX 42.2/100Mixed-negative evidence65% evidence BREAKING OUT 8.6/35 Revenue -1.3% · PAT -31% · OPM change -4.3 pp 83% evidence 11.0/25 ROCE 1.2% · OPM 7.2% 76% evidence 10.4/20 P/E 32.7× · PEG — 15% evidence 12.2/20 RS sector 1.7% · RS bench 1% · 1Y -3.7%11 of 12 weeks ahead 70% evidence
Exact sum: 8.6 + 11 + 10.4 + 12.2 = 42.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
19Doximity, Inc.DOCS 40.7/100Mixed-negative evidence81% evidence ASLEEP 11.6/35 Revenue 13% · PAT -11.7% · OPM change -18.1 pp 83% evidence 15.9/25 ROCE 2.4% · OPM 17.1% 76% evidence 11.3/20 P/E 23.8× · PEG 1.84 65% evidence 1.9/20 RS sector -49.3% · RS bench -50.6% · 1Y -67.1%0 of 12 weeks ahead 100% evidence
Exact sum: 11.6 + 15.9 + 11.3 + 1.9 = 40.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
20Talkspace, Inc.TALK 40.6/100Mixed-negative evidence64% evidence ASLEEP 12.9/35 Revenue 22.7% · PAT -66.7% · OPM change -9.5 pp 62% evidence 6.0/25 ROCE -6.2% · OPM -11.6% 76% evidence 8.5/20 P/E 517.5× · PEG — 15% evidence 13.2/20 RS sector 8.3% · RS bench 12% · 1Y 106%0 of 12 weeks ahead 100% evidence
Exact sum: 12.9 + 6 + 8.5 + 13.2 = 40.6 · Decision use: Price leads the evidence: RS versus the benchmark is 12%, but earnings trajectory is weak. Wait for revenue and profit confirmation.
21HeartFlow, Inc.HTFL 39.7/100Thin evidence · provisional55% evidence ASLEEP 20.1/35 Revenue 40.4% · PAT — · OPM change -9.1 pp 62% evidence 4.0/25 ROCE -13.2% · OPM -56.1% 76% evidence 10.0/20 P/E — · PEG — 0% evidence 5.6/20 RS sector -18% · RS bench -17.4% · 1Y -12.5%6 of 12 weeks ahead 70% evidence
Exact sum: 20.1 + 4 + 10 + 5.6 = 39.7 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
22Schrödinger, Inc.SDGR 37.5/100Thin evidence · provisional58% evidence BREAKING OUT 15.8/35 Revenue 10.9% · PAT — · OPM change 2.2 pp 62% evidence 4.9/25 ROCE -9.4% · OPM -83.3% 76% evidence 9.6/20 P/E 66.3× · PEG — 15% evidence 7.2/20 RS sector -11.9% · RS bench -12.2% · 1Y -18.5%10 of 12 weeks ahead 70% evidence
Exact sum: 15.8 + 4.9 + 9.6 + 7.2 = 37.5 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
23Tempus AI, Inc.TEM 37.1/100Thin evidence · provisional55% evidence ASLEEP 19.0/35 Revenue — · PAT — · OPM change 2.6 pp 45% evidence 5.4/25 ROCE -4.8% · OPM -24.3% 76% evidence 10.0/20 P/E — · PEG — 0% evidence 2.7/20 RS sector -32.9% · RS bench -33.2% · 1Y -22.7%3 of 12 weeks ahead 100% evidence
Exact sum: 19 + 5.4 + 10 + 2.7 = 37.1 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
24Spok Holdings, Inc.SPOK 36.0/100Mixed-negative evidence75% evidence BASING 8.4/35 Revenue -1.4% · PAT -18.8% · OPM change -9.2 pp 83% evidence 13.0/25 ROCE 1.6% · OPM 7.4% 76% evidence 9.7/20 P/E 18.2× · PEG 2.25 65% evidence 4.9/20 RS sector -23.7% · RS bench -23.5% · 1Y -38.4%0 of 12 weeks ahead 70% evidence
Exact sum: 8.4 + 13 + 9.7 + 4.9 = 36 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
25Claritev CorporationCTEV 36.0/100Thin evidence · provisional55% evidence ASLEEP 13.1/35 Revenue 5.8% · PAT — · OPM change -3.1 pp 62% evidence 8.9/25 ROCE 0.1% · OPM 2.7% 76% evidence 10.0/20 P/E — · PEG — 0% evidence 4.0/20 RS sector -33.5% · RS bench -35.5% · 1Y -53.5%8 of 12 weeks ahead 70% evidence
Exact sum: 13.1 + 8.9 + 10 + 4 = 36 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
26Certara, Inc.CERT 35.6/100Thin evidence · provisional58% evidence BREAKING OUT 12.0/35 Revenue 6.8% · PAT — · OPM change -11.2 pp 62% evidence 8.8/25 ROCE -0.3% · OPM -4% 76% evidence 8.7/20 P/E 174.6× · PEG — 15% evidence 6.1/20 RS sector -14.8% · RS bench -15.5% · 1Y -28.7%6 of 12 weeks ahead 70% evidence
Exact sum: 12 + 8.8 + 8.7 + 6.1 = 35.6 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
27Evolent Health, Inc.EVH 32.7/100Thin evidence · provisional55% evidence ASLEEP 11.3/35 Revenue -21.3% · PAT — · OPM change -1.8 pp 62% evidence 8.1/25 ROCE -0.6% · OPM -2.1% 76% evidence 10.0/20 P/E — · PEG — 0% evidence 3.3/20 RS sector -42.2% · RS bench -43.6% · 1Y -65.4%10 of 12 weeks ahead 70% evidence
Exact sum: 11.3 + 8.1 + 10 + 3.3 = 32.7 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
28LifeMD, Inc.LFMD 31.0/100Thin evidence · provisional58% evidence ASLEEP 12.3/35 Revenue 36.9% · PAT — · OPM change -15.5 pp 62% evidence 4.0/25 ROCE -53.7% · OPM -17.8% 76% evidence 9.4/20 P/E 72.2× · PEG — 15% evidence 5.3/20 RS sector -21.5% · RS bench -21.8% · 1Y -42.8%7 of 12 weeks ahead 70% evidence
Exact sum: 12.3 + 4 + 9.4 + 5.3 = 31 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
29Teladoc Health, Inc.TDOC 41.9/100Thin evidence · provisional49% evidence ASLEEP 18.6/35 Revenue — · PAT — · OPM change 9.1 pp 45% evidence 6.8/25 ROCE -1.9% · OPM -10.1% 76% evidence 10.0/20 P/E — · PEG — 0% evidence 6.5/20 RS sector -14.6% · RS bench -14.6% · 1Y -3.6%10 of 12 weeks ahead 70% evidence
Exact sum: 18.6 + 6.8 + 10 + 6.5 = 41.9 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.

Missing observations are not scored as bad. Their missing weight lowers confidence and pulls the final score toward neutral. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led S&P 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step curve the sector itself is placed on — basing, turning, breaking out, leader, fading, asleep — read from how many weeks running it has led S&P 500 and whether that lead is widening or shrinking. It describes where the PRICE stands, not the earnings trajectory and not a recommendation, and it is left blank for a company whose weekly history is too short or too stale to read.

16 · Frequently asked questions

Frequently asked questions

What is Veeva Systems Inc.'s stock price today?

Veeva Systems Inc. trades at $212, −24.7% over the past year. The company is valued at $34.0 B. The stock sits at 42% of its 52-week range of $151–$296, +4.3% versus its 200-day average. On the tape, the price is topping out, 1 weeks in. — as of 5 August 2026.

What were Veeva Systems Inc.'s latest quarterly results?

Veeva Systems Inc. reported revenue of $0.9 B and net profit of $0.3 B for the Apr 26 quarter. Revenue rose 15.8% and profit rose 13.0% year on year. Earnings per share were $1.57. The operating margin was 30.7%, 0.4 pp higher than a year earlier. — as of 5 August 2026.

What is Veeva Systems Inc.'s revenue?

Veeva Systems Inc. reported revenue of $0.9 B in the Apr 26 quarter, +15.8% year on year. For the full FY26 fiscal year, revenue was $3.2 B (+16.4%). Over the last 4 years revenue compounded at 14.7% a year. — as of 5 August 2026.

What is Veeva Systems Inc.'s profit?

Veeva Systems Inc. earned $0.3 B of net profit in the Apr 26 quarter, +13.0% year on year — the 9th straight quarter of growth. Full-year FY26 profit was $0.9 B. The operating margin ran 30.7% in the latest quarter. — as of 5 August 2026.

What is Veeva Systems Inc.'s market cap?

Veeva Systems Inc.'s market capitalisation is $34.0 B at a stock price of $212. Market cap is the share price multiplied by shares outstanding, so it is restated whenever the price moves. — as of 5 August 2026.

What is Veeva Systems Inc.'s P/E ratio?

Veeva Systems Inc. trades at a P/E of 37.6×, at the 12th percentile of its own 4-year range, against a long-run median of 57.4×. This is a comparison with the stock's own history, not a value call — as of 5 August 2026.

Does Veeva Systems Inc. pay a dividend?

No — Veeva Systems Inc. has declared no dividend per share in any of its last 12 reported quarters, so there is no payout history and no yield to quote. That is a reading of the filed statements, not an estimate. — as of 5 August 2026.

Is Veeva Systems Inc. overvalued?

On its own history, Veeva Systems Inc. looks cheap against its own history: its P/E of 37.6× has been cheaper only 12% of the time in 4 years (long-run median 57.4×). That is a percentile read against the stock's own past, not a price opinion or a direction call. One caveat: margins are the best this company has ever printed — cheap on record margins is not the same thing as cheap. — as of 5 August 2026.

Is Veeva Systems Inc. growing?

Yes — Veeva Systems Inc. is growing: latest-quarter revenue +15.8% year on year, profit +13.0%, and the margin +0.4 pp at 30.7%. The 4-year compound rates are 14.7% (revenue) and 20.6% (profit). The earnings engine currently reads: improving — as of 5 August 2026.

How is Veeva Systems Inc. performing?

Veeva Systems Inc. is topping out, 1 weeks in. Its latest quarter's revenue rose 15.8% and profit rose 13.0% year on year. Against the S&P 500 it has been ahead on a trailing-13-week view for 5 weeks. This describes what the data did, not a rating. — as of 5 August 2026.

What stage is Veeva Systems Inc. in?

Mixed — no clean majority across the growth curves, ROCE holding at 9.9% — the per-curve reads carry the story. The read comes from the last 12 quarters of growth (revenue growth +16.1% latest, profit growth +19.0% latest, eps growth +18.9% latest) plus the ROCE curve, classified by deterministic rules — a trajectory read, not a buy or sell call — as of 5 August 2026.

Is Veeva Systems Inc. in an uptrend?

It is stalling — the price is topping out (week 1 of stage 3), trading +4.3% versus its 200-day average and at 42% of its 52-week range. Price stages cycle base → advance → top → decline, and the stage names where this stock sits in that cycle — as of 5 August 2026.

Is Veeva Systems Inc. beating the market?

On recent form, yes — Veeva Systems Inc. has been ahead of the S&P 500 on a trailing-13-week view for 5 straight weeks, the same metric the week-by-week ribbon on this page draws. Separately, on the cumulative view: over the last 10.1 years the stock moved +467% against the S&P 500's +263% — ahead of the index over the full window. — as of 5 August 2026.

Will Veeva Systems Inc.'s stock price go up?

This page publishes no price forecast for Veeva Systems Inc. What it measures instead: the stock price is $212, the price is topping out 1 weeks in. Its P/E of 37.6× sits at the 12th percentile of its own 4-year range. Direction is not something this site claims to know. — as of 5 August 2026.

Is the market betting against Veeva Systems Inc.?

Somewhat — short interest is 5.3% of Veeva Systems Inc.'s tradable float, about 3.2 days to cover at typical volumes. A moderate reading: some money is positioned against it. With no quarter-by-quarter holder register here, short interest is the cleanest crowd read we hold — as of 5 August 2026.

Does Veeva Systems Inc. have too much debt?

No — Veeva Systems Inc.'s debt-to-equity is 0.01. A year-by-year borrowings ladder is not in our numbers for this stock, so the latest reading is the cleanest hold. The returns on this page are earned, not borrowed — as of 5 August 2026.

What is Veeva Systems Inc.'s cash flow?

Veeva Systems Inc. generated $1.4 B of operating cash flow in FY26 and $1.4 B of free cash flow after null of capital spending. Reported profit that year was $0.9 B, so operating cash ran ahead of profit. — as of 5 August 2026.

Is Veeva Systems Inc.'s profit real cash?

Yes — over the last 3 fiscal years, 159% of Veeva Systems Inc.'s reported profit arrived as operating cash. In FY26, operating cash was $1.4 B against reported profit of $0.9 B. The cash then goes into a mix of the working-capital cycle and capacity. Cash-flow resolution is annual — as of 5 August 2026.

How financially safe is Veeva Systems Inc.?

On the balance sheet, the Z-score reads 15.38 — above roughly 3 is safe, below roughly 1.8 is the distress zone. That sits well clear of trouble. — as of 5 August 2026.

Where is Veeva Systems Inc. in its business cycle?

Veeva Systems Inc.'s FY26 operating margin was 28.7%, against a 5-year band of 18.2%–28.7%: the top of the band — a record year. Record profitability is late-cycle territory: every ratio flatters at the top, and the story leans on margins holding. The latest quarter ran 30.7%. Profitability versus a company's own long band is the cleanest cycle clock this page holds — as of 5 August 2026.

What could break the Veeva Systems Inc. story?

The sharpest disagreement: annual EPS moved +25.9% against a −24.7% price move — the market has not yet caught up with the delivery. Mechanically, two Friday closes in a row below the 200-day average would end the price trend — that is the exit rule this page tracks — as of 5 August 2026.

Is Veeva Systems Inc. a stock worth studying right now?

This is not investment advice. The machine read: Veeva Systems Inc.'s earnings have outrun its stock. EPS grew +25.9% in a year against a −24.7% price move. The sharpest open question: whether the price catches up with earnings that have already moved. Every number on this page is drawn deterministically from the raw series, with no forecasts and no price opinions — as of 5 August 2026.

Chat with this pageChat with pageChatChatGPTClaudePerplexityGoogle AI